Curevo has set its sights on competing with GSK’s shingles vaccine dominance by securing $110m and securing a former ...

The recombinant zoster vaccine is effective in preventing herpes zoster in adults aged 50 years or older with rheumatoid ...

Moncef Slaoui, who ran the Operation Warp Speed Covid vaccine effort, is becoming chair of Curevo, a company developing a new ...

The shingles vaccine is recommended for healthy adults age 50 or older, and also for anyone age 19 years or older who has a ...

Curevo, a Seattle-based biotech startup developing a vaccine against shingles, raised $110 million in a Series B ...

In its effort to rival GSK’s shingles vaccine Shingrix, Curevo Vaccine has circled up $110 million and recruited two former ...

DEAR DR. ROACH: I am a 79-year-old woman who received the original Zostavax vaccine around 2010. Then, when the newer, improved Shingrix vaccine became available, I was given the two-shot series ...

Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new investors ...

Although doctors should read these carefully and act on them appropriately, important findings can be overlooked sometimes.

AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to ...

As its candidate advances through clinical trials, Curevo is setting up future rivalry with GSK’s Shingrix (zoster vaccine recombinant) – the only US Food and Drug Administration (FDA ...

Seattle, USA-based biotech Curevo Vaccine, which is developing varicella zoster virus (VZV) vaccines with improved tolerability, today announces the closing of a $110 million Series B round to advance ...